These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 35974399)

  • 21. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
    Streit WJ; Braak H; Xue QS; Bechmann I
    Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated microglia mitigate Aβ-associated tau seeding and spreading.
    Gratuze M; Chen Y; Parhizkar S; Jain N; Strickland MR; Serrano JR; Colonna M; Ulrich JD; Holtzman DM
    J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34100905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Combination of Heavy Metals and Intracellular Pathway Modulators Induces Alzheimer Disease-like Pathologies in Organotypic Brain Slices.
    Korde DS; Humpel C
    Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spreading of Alzheimer tau seeds is enhanced by aging and template matching with limited impact of amyloid-β.
    Nies SH; Takahashi H; Herber CS; Huttner A; Chase A; Strittmatter SM
    J Biol Chem; 2021 Oct; 297(4):101159. PubMed ID: 34480901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and App
    Nuñez-Diaz C; Andersson E; Schultz N; Pocevičiūtė D; Hansson O; ; Nilsson KPR; Wennström M
    Alzheimers Res Ther; 2024 Jan; 16(1):4. PubMed ID: 38167557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J
    Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.
    Thaker U; McDonagh AM; Iwatsubo T; Lendon CL; Pickering-Brown SM; Mann DM
    Neuropathol Appl Neurobiol; 2003 Feb; 29(1):35-44. PubMed ID: 12581338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmission of amyloid-beta and tau pathologies is associated with cognitive impairments in a primate.
    Lam S; Petit F; Hérard AS; Boluda S; Eddarkaoui S; Guillermier M; ; Buée L; Duyckaerts C; Haïk S; Picq JL; Dhenain M
    Acta Neuropathol Commun; 2021 Oct; 9(1):165. PubMed ID: 34641980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex.
    Welikovitch LA; Do Carmo S; Maglóczky Z; Szocsics P; Lőke J; Freund T; Cuello AC
    Acta Neuropathol; 2018 Dec; 136(6):901-917. PubMed ID: 30362029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuritic Plaques - Gateways to Understanding Alzheimer's Disease.
    Tsering W; Prokop S
    Mol Neurobiol; 2024 May; 61(5):2808-2821. PubMed ID: 37940777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Alzheimer-type lesions in cognitively normal subjects.
    Tsartsalis S; Xekardaki A; Hof PR; Kövari E; Bouras C
    Neurobiol Aging; 2018 Feb; 62():34-44. PubMed ID: 29107845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voluntary Running Attenuates Memory Loss, Decreases Neuropathological Changes and Induces Neurogenesis in a Mouse Model of Alzheimer's Disease.
    Tapia-Rojas C; Aranguiz F; Varela-Nallar L; Inestrosa NC
    Brain Pathol; 2016 Jan; 26(1):62-74. PubMed ID: 25763997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice.
    Li J; Deng J; Sheng W; Zuo Z
    Pharmacol Biochem Behav; 2012 Jun; 101(4):564-74. PubMed ID: 22425595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
    Schweig JE; Yao H; Beaulieu-Abdelahad D; Ait-Ghezala G; Mouzon B; Crawford F; Mullan M; Paris D
    Acta Neuropathol Commun; 2017 Sep; 5(1):69. PubMed ID: 28877763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype.
    Pletnikova O; Kageyama Y; Rudow G; LaClair KD; Albert M; Crain BJ; Tian J; Fowler D; Troncoso JC
    Neurobiol Aging; 2018 Nov; 71():72-80. PubMed ID: 30099348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.